98 mn Indians will have diabetes by 2030: Lancet

98 million Indians will suffer from diabetes by 2030, says Study

98 million Indians will suffer from diabetes by 2030, says Study

By the year 2030, 511 million adults around the world will have type 2 diabetes and 79 million of them will need insulin to manage their condition.

"These estimates suggest that current levels of insulin access are highly inadequate compared to projected need, particularly in Africa and Asia, and more efforts should be devoted to overcoming this looming health challenge", said Basu.

As the number of people living with diabetes continues to rise, the access to insulin needed to meet growing demand will fall short, a new study predicts.

Globally China, India and the United States with the highest population are more prone to diabetes 2 due to the obesity and the sedentary work lifestyle.

Insulin is used to treat those with Type 1 diabetes and some people with Type 2 diabetes, which is linked to obesity and little physical activity.

In cases of type 2 diabetes, the body produces insulin but can't process it properly.

Diabetes affects more than 382 million people worldwide. The study found that the rise in the number of people affected by the disease is likely to rise by around 20 per cent over the people affected now.

A global diabetes epidemic is fueling record demand for insulin, but tens of millions will not get the injections they need unless there is a dramatic improvement in access and affordability, a new study concludes. "Despite the UN's commitment to treat non-communicable diseases and ensure universal access to drugs for diabetes, across much of the world insulin is scarce and unnecessarily hard for patients to access", said Dr Sanjay Basu, a scientist at the Stanford University and the lead author of the study, Eurekalert.org reported.

"Despite the UN's commitment to treat non-communicable diseases and ensure universal access to drugs for diabetes, across much of the world insulin is scarce and unnecessarily hard for patients to access".

Global insulin supply is dominated by three companies - Novo Nordisk, Sanofi and Eli Lilly - which have various programs to try to improve access to their products. The creators caution that procedures to make insulin all the more broadly accessible and reasonable will be hard to guarantee that request is met. Unless governments commence inventiveness to make insulin accessible and economical, then its application is going to be far from appropriate.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.